drugset / Trial / NCT01118624

Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer

NCT01118624

Phase 2 Completed 22 enrolled Acrotech Biopharma Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the efficacy (ability to provide a beneficial treatment of the disease) of pralatrexate for the treatment of female patients with advanced or metastatic breast cancer who have failed prior chemotherapy. Patients will receive vitamin B12 and folic acid supplementation.

Timeline

Start
2010-03
Primary completion
2012-04
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Pralatrexate Other / unclassified 190 mg/m2 Intravenous

Indications